Coronary Artery Disease Pipeline Offers Promising New Treatment Options as 23+ Leading Players are Working in the Space | DelveInsight
Coronary artery disease Pipeline constitutes 23+ key companies continuously working towards developing 25+ coronary artery disease treatment therapies, analyzes DelveInsight
/EIN News/ -- New York, USA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Coronary Artery Disease Pipeline Offers Promising New Treatment Options as 23+ Leading Players are Working in the Space | DelveInsight
Coronary artery disease Pipeline constitutes 23+ key companies continuously working towards developing 25+ coronary artery disease treatment therapies, analyzes DelveInsight
DelveInsight’s 'Coronary Artery Disease Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline coronary artery disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the coronary artery disease pipeline domain.
Key Takeaways from the Coronary Artery Disease Pipeline Report
- DelveInsight’s coronary artery disease pipeline report depicts a robust space with 23+ active players working to develop 25+ pipeline therapies for coronary artery disease treatment.
- Key coronary artery disease companies such as Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences, and others are evaluating new drugs for coronary artery disease to improve the treatment landscape.
- Promising coronary artery disease pipeline therapies in various stages of development include Selatogrel, XTR 003, AdVEGFXC1, Revacept, XTR004, MCRcI stem cells, PET MPI, Inclisiran, AZD-5718, VM202, Evolocumab, Ad5-FGF4, REG-101, and others.
- In June 2022, Idorsia announced the subcutaneous administration of selatogrel by a healthcare professional has been studied in two Phase II clinical studies in patients with stable coronary artery disease (CAD) and in patients with AMI.
- In February 2022, Regio Biosciences (Regio) entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic acting on reverse cholesterol transport (RCT). Under the terms of the agreement, AstraZeneca will provide an exclusive license to Regio for further development of REG-101, previously known as MEDI5884, to address patients with high unmet medical needs, including PAD and cardiovascular disease.
- In March 2021, XyloCor Therapeutics raised $22.6 million to study a gene therapy designed to deliver VEGF to heart cells. The funding to support a clinical trial to assess the use of the VEGF gene therapy, XC001, to boost the effectiveness of CABG, a surgical procedure that treats coronary heart disease by diverting blood around narrowed or clogged arteries.
Request a sample and discover the recent advances in coronary artery disease treatment drugs @Coronary Artery Disease Pipeline Report
The coronary artery disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage coronary artery disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the coronary artery disease clinical trial landscape.
Coronary Artery Disease Overview
Coronary artery disease (CAD) is the most common type of heart disease in the United States. It is also known as coronary heart disease or ischemic heart disease. Plaque buildup in the walls of the arteries that supply blood to the heart (called coronary arteries) and other parts of the body is the major reason responsible for coronary artery disease causes.
The most common coronary artery disease symptoms are angina, or chest pain and discomfort. An electrocardiogram (ECG) is the most common way for coronary artery disease diagnosis. It is also possible to examine the heart with an ultrasound scan (echocardiography) or another imaging technique.
The primary goals of coronary artery disease treatment are to alleviate symptoms and prevent complications. Medication can help to alleviate the coronary artery disease symptoms and limitations of stable angina. This is accomplished through the use of beta-blockers, calcium channel blockers, and nitrates.
Find out more about coronary artery disease guidelines @Coronary Artery Disease Treatment Guidelines
A snapshot of the Coronary Artery Disease Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Evolocumab | Amgen | Phase III | PCSK9 protein inhibitor | Subcutaneous |
| Revacept | AdvanceCor | Phase II | Platelet membrane glycoprotein VI inhibitors | Intravenous |
| Atuliflapon | AstraZeneca | Phase II | 5-lipoxygenase activating protein inhibitors | Oral |
| Selatogrel | Idorsia Pharmaceuticals | Phase II | Purinoceptor P2Y12 antagonists | Subcutaneous |
| AdVEGFXC1 | XyloCor Therapeutics | Preclinical | Gene transference; Vascular endothelial growth factor replacements | NA |
Learn more about the emerging coronary artery disease pipeline therapies @Coronary Artery Disease Clinical Trials
Coronary Artery Disease Therapeutics Assessment
The coronary artery disease pipeline report proffers an integral view of coronary artery disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Coronary Artery Disease Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
- Therapeutics Assessment By Mechanism of Action: Purinoceptor P2Y12 antagonists, 5-lipoxygenase activating protein inhibitors, Positron-emission tomography enhancers, Gene transference, Vascular endothelial growth factor replacements, Platelet membrane glycoprotein VI inhibitors, Radionuclide imaging enhancers
- Key Coronary Artery Disease Companies: Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, Honya Medical Inc, Novartis Pharmaceuticals, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, and others
- Key Coronary Artery Disease Pipeline Therapies: Selatogrel, XTR 003, AdVEGFXC1, Revacept, XTR004, MCRcI® stem cells, PET MPI, Inclisiran, AZD-5718, VM202, Evolocumab, Ad5-FGF4, and others
Dive deep into rich insights for new drugs for coronary artery disease treatment, visit @Coronary Artery Disease Medications
Table of Contents
| 1. | Coronary Artery Disease Pipeline Report Introduction |
| 2. | Coronary Artery Disease Pipeline Report Executive Summary |
| 3. | Coronary Artery Disease Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Coronary Artery Disease Clinical Trial Therapeutics |
| 6. | Coronary Artery Disease Pipeline: Late Stage Products (Phase III) |
| 6.1 | Evolocumab: Amgen |
| 7. | Coronary Artery Disease Pipeline: Mid Stage Products (Phase II) |
| 7.1 | Atuliflapon: AstraZeneca |
| 8. | Coronary Artery Disease Pipeline: Early Stage Products (Phase I) |
| 8.1 | Drug name: Company name |
| 9. | Coronary Artery Disease Pipeline Therapeutics Assessment |
| 10. | Inactive Products in the Coronary Artery Disease Pipeline |
| 11. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 12. | Key Companies |
| 13. | Key Products in the Coronary Artery Disease Pipeline |
| 14. | Unmet Needs |
| 15. | Market Drivers and Barriers |
| 16. | Future Perspectives and Conclusion |
| 17. | Analyst Views |
| 18. | Appendix |
For further information on the coronary artery disease pipeline therapeutics, reach out @Coronary Artery Disease Treatment Drugs
Related Reports
End-stage Coronary Artery Disease Market
End-stage Coronary Artery Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key end-stage coronary artery disease companies including AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, Novartis Pharmaceuticals, among others.
Coronary Artery Disease Epidemiology Forecast
Coronary Artery Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted coronary artery disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Peripheral Artery Disease Pipeline
Peripheral Artery Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key peripheral artery disease companies, including Novo Nordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, among others.
Peripheral Artery Disease Market
Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key peripheral artery disease companies including NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, among others.
Peripheral Artery Disease Epidemiology
Peripheral Artery Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted peripheral artery disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight
Related Healthcare Blogs
Upcoming Cardiovascular Diseases Drugs
Key Companies in the Cardiology Segment
Top Cardiac Devices in the Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
